Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Diabetes Mellitus, Hypertension, Hyperli...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible. This research project aims to see whether a pharmacist service can help improve diabetes management in people with type 2 diabetes compared to usual care from their family physician or nurse practitionner. The potential impact of this project is to empower people with type 2 diabetes to understand their condition, it's management, and to achieve target blood sugar levels, which will ultimately reduce the risk of diabetes-related complications.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Other: Pharmacist-led diabetes care pathway — articipants in the intervention arm will receive the care using a shared decision-making pharmacist care pathway approach designed to guide type 2 diabetes management to achieve target A1C levels and reduce the risk of diabetes-related complications. The pharmacist care pathway is modelled after the Canadian Diabetes Association Guidelines22. This pathway (tool) will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to achieve target A1C levels and reduce the risk of diabetes-related complications. This will occur through follow-ups every 6 weeks for six months duration.

Primary Outcomes

  • A1C change (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-13
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Principal Investigators:
  • Ross Tsuyuki, BScPharm, PharmD, MSc (PRINCIPAL_INVESTIGATOR) - University of Alberta
Contact Information
Study Contact:
Stephanie Gysel, BScPharm, PharmD
403-993-6678
sgysel@ualberta.ca
Ross Tsuyuki, BScPharm, PharmD, MSc
780-492-8526
rtsuyuki@ualberta.ca
Ross Tsuyuki, BScPharm, PharmD, MSc.
780-994-8772
rtsuyuki@ualberta.ca
University of Alberta
Interventions
  • Other: Pharmacist-led diabetes care pathway — articipants in the intervention arm will receive the care using a shared decision-making pharmacist care pathway approach designed to guide type 2 diabetes management to achieve target A1C levels and reduce the risk of diabetes-related complications. The pharmacist care pathway is modelled after the Canadian Diabetes Association Guidelines22. This pathway (tool) will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to achieve target A1C levels and reduce the risk of diabetes-related complications. This will occur through follow-ups every 6 weeks for six months duration.
Study Locations (1 sites)
University of Alberta, Edmonton, Alberta Canada
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged 18 years or older. 2. Individuals with type 2 diabetes. 3. Individuals with type 2 diabetes not reaching HbA1c target of under 7.0% Exclusion Criteria: 1. Individuals with type 1 diabetes, gestational diabetes, or other forms of diabetes that are not type 2 diabetes. 2. Pregnant individuals. 3. Individuals at their HbA1c target (HbA1c under 7.0%) or those with a limited life expectancy, frailty, or lack hypoglycemic awareness (i.e., those with an A1c target above 7.0%) . 4. Individuals unable to provide consent or who are unwilling to attend follow-up visits.
Conditions Hypertension, Hyperglycemia, Hyperlipide...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study conducted a six-month exploratory clinical trial to evaluate the impact of an exercise prescription mini-program, based on the "Exercise Guidelines for the 'Four Highs'", on the physical activity levels and related health indicators of patients with hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia in primary healthcare settings in China.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Enhanced Mini-Program Intervention — physician training/assessment + patient exercise guidance via the mini-program + patient social support group activities
  • Behavioral: Enhanced Control — physicians receiving training/assessment in addition to conducting patient exercise guidance autonomously

Primary Outcomes

  • Change in mean daily step count (from baseline to Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2026-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China National Center for Cardiovascular Diseases
Contact Information
Study Contact:
Tian
86+ 88319206
sigaoresearch@163.com
Tian
86+88319206
sigaoresearch@163.com
Fuwai Hospital, Chinese Academy of MedicL Sciences
Interventions
  • Behavioral: Enhanced Mini-Program Intervention — physician training/assessment + patient exercise guidance via the mini-program + patient social support group activities
  • Behavioral: Enhanced Control — physicians receiving training/assessment in addition to conducting patient exercise guidance autonomously
Study Locations (1 sites)
Fuwai Hospital, Chinese Academy of MedicL Sciences, Beijing, 100061 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older. 2. Willing to participate in the study and able to provide written informed consent. 3. Diagnosed with at least one of the following "Four Highs" conditions: Hypertension: Diagnosed primary hypertension, defined as seated office SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg on at least three non-consecutive days, or currently taking antihypertensive medication. Blood pressure must be controlled while on four or more antihypertensive agents. Diabetes Mellitus: Diagnosed diabetes, defined as having typical symptoms plus random plasma glucose ≥ 11.1 mmol/L, or fasting plasma glucose ≥ 7.0 mmol/L, or 2-hour plasma glucose during OGTT ≥ 11.1 mmol/L, or HbA1c ≥ 6.5%, or currently taking glucose-lowering medication. HbA1c level must be between 6.5% and 13.0%. Hyperlipidemia: Diagnosed hyperlipidemia, defined as total cholesterol (TC) ≥ 6.22 mmol/L, or LDL-C ≥ 4.14 mmol/L, or HDL-C \< 1.04 mmol/ L, or triglycerides (TG) \> 2.26 mmol/L, or currently taking lipid-lowering medication. Hyperuricemia: Diagnosed hyperuricemia, defined as a fasting serum uric acid level \> 420 μmol/L (7 mg/dL) in men and postmenopausal women, or \> 360 μmol/L (6 mg/dL) in premenopausal women, on two non-consecutive days under a normal purine diet, or currently taking urate-lowering medication. 4. Capable of using a smartphone. 5. A local permanent resident who receives basic public health service management at the designated community health center/station or township hospital. 6. Has not engaged in regular moderate- to vigorous-intensity physical activity (defined as at least 30 minutes per session, on at least 3 days per week) in the past three months. Exclusion Criteria: Patients meeting any of the following criteria will be excluded: 1. History or acute episode of cardiovascular or cerebrovascular disease, including: angina pectoris, myocardial infarction, coronary revascularization surgery, stroke (ischemic or hemorrhagic, including transient ischemic attack), symptomatic peripheral arterial disease requiring surgery or diagnosed by vascular imaging, ventricular arrhythmia, uncontrolled atrial fibrillation, congestive heart failure (New York Heart Association Class III or IV), hypertrophic cardiomyopathy, history of aneurysm with diameter ≥ 5.5 cm or prior aneurysm surgery. 2. Current malignant tumor or history of malignant tumor within the past five years. 3. Contraindications to exercise, such as bone and joint diseases. 4. Severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), restricted lung volume (due to obesity, pregnancy, or spinal deformity), or cystic fibrosis. 5. Neuromuscular and degenerative diseases, such as muscular dystrophy, poliomyelitis, and dementia. 6. Severe mental illness, including schizophrenia, bipolar disorder, eating disorders, or depression (with hospitalization for the condition within the past 6 months). 7. Movement and other neurological disorders, such as Huntington's disease, torsion dystonia, Parkinson's disease, and certain epileptic disorders. 8. Severe comorbidities with a life expectancy of less than 24 months. 9. Plans to relocate from the area within the next three months. 10. Participation in other physical activity level intervention programs within the six months prior to the screening visit. 11. Current participation in another randomized clinical trial. 12. Any other condition that, in the investigator's judgment, may interfere with adherence to the trial protocol.
Conditions Living Kidney Donation, Hypertension, Ne...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn if PRAT thickness is a marker of visceral obesity and its influence on donors' kidney function and blood pressure in living kidney donors. Population includes male/female, 18 years and up, living kidney donors scheduled for nephrectomy within 6 months. The main area it aims to help in, is future care managing blood pressure and obesity in living kidney transplant donors. Primary Hypothesis: We hypothesize that Perirenal Fat Thickness (PRAT) may exhibit expansion, remodeling and inflammation that can negatively affect renal outcomes in LKDs. Researchers will compare PRAT morphology and inflammation in LKDs with low and high PRAT thickness. We will also correlate PRAT thickness with renal outcomes including vascular remodeling, at the time of donation and worsening hypertension and inadequately increased compensatory GFR of the LKD at 4-6 months post-donation. Participants will be separated into one of two groups depending on their PRAT measurement and asked to give samples of their blood, perinephric fat, and urine as research samples. Clinically we will abstract data up to 12 months prior and 6 months after their nephrectomy that includes laboratory findings, CT measurements, vitals, exam data, demographics, medical history and current medications.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Proinflammatory Macrophage infiltrations of Perinephric Fat for LKD (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-10
Completion: 2028-02-10
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Aleksandra Kukla, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Jackie Reiter
507-538-2224
reiter.jacqulyn@mayo.edu
Maulik Lathiya, MBBS
lathiya.maulik@mayo.edu
Jackie Reiter
507-538-2224
REITER.JACQULYN@MAYO.EDU
Mayo Clinic
Interventions
N/A
Study Locations (1 sites)
Mayo Clinic, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Participants in this study will be restricted to living kidney transplant donors (LKDs). . Exclusion Criteria: * Those who do not meet Mayo Clinic Rochester's clinical criterion for donor nephrectomy. * \>10% weight change between the donor evaluation and donor nephrectomy * Individuals who are pregnant or are planning to become pregnant * Inability to comply with study procedures or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.
Conditions Glaucoma, Diabetic Retinopathy (DR), Hyp...
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life. The primary conditions contributing to visual impairment and blindness include cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), refractive error, and presbyopia. Early detection of eye disease can provide substantial benefits in prompting treatment to reduce progression and mitigate disability. Compared with other regions, South Asia has the most cases of visual impairment due to cataracts and uncorrected refractive error. The combination of poverty, poor living and working environments, and limited health care access have long endangered eye health in Bangladesh. Coastal Bangladesh is particularly impacted by eye disease due to economic deprivation and limited healthcare access. The coastal population mostly works in fishing and agriculture, have prolonged sunlight exposure, and inadequate occupational eye protection. This low-lying region, with 35 million people, is especially vulnerable to climate disasters and global warming. High rates of chronic disease, especially diabetes mellitus Type 2 and hypertension, coupled with limited screening and treatment, shape the area's health profile, with the increasing prevalence of eye diseases such as DR, glaucoma, and visual impairment. To address the issues of poor health, accessibility, and affordability of eye care, Artificial Intelligence (AI) applications, such as Artificial Intelligence (AI)-assisted fundus imaging, can be applied in eye screening. Medical AI applications have the potential to improve the quality and efficiency of healthcare, reduce healthcare costs, optimize treatment plans, and bolster the development of primary healthcare. They can identify presumptive DR, hypertensive retinopathy (HR), AMD, and glaucoma by analyzing the retina and optic disc of fundus images with moderate accuracy and high efficiency, thus helping address the lack of local eye care professionals. Data Yakka developed a human-AI collaboration that delivers affordable and transformative community-based eye screening to underserved communities in the coastal Bangladesh region of Char Fasson. The "Amar Chokh Amar Alo" (My Eyes, My Light) initiative creates and implements comprehensive eye screening that combines AI-assisted eye screening and grassroots partnerships with trusted non-health non-governmental organizations (NGOs). It has three objectives: 1) Enhancing accessibility and affordability of eye screening; 2) Supporting high quality and efficient treatment of those problems detected via screening, 3) Collecting fundus images to refine or train AI algorithms in the future. This project was designed to evaluate the feasibility, performance, equity, and cost of this model of eye screening and its implications for global eye disease. The implementation of participant recruitment, data collection, screening, and follow-up…

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Multimodal Screening for Eye Disease — The eye disease screening process involved twelve distinct steps were that organized through a corresponding software platform (electronic health record). These steps included: (1) community awareness campaign, (2) participant registration, (3) blood pressure and finger-stick blood glucose measurement, (4) basic vision test, (5) on-site optometrist evaluation, (6) obtaining informed consent for imaging, (7) fundus imaging, (8) automated AI-based disease detection, (9) on-site ophthalmologist examination, (10) remote eye specialist review, (11) on-site counselor discussion, (12) referral for local surgery. This standardized protocol promoted the alignment of eye screening with data gathering and ongoing follow-up eye care interventions. All participants were offered steps 1 to 5. Those participants eligible for fundus imaging (Steps 6-8) included those with diabetes, hypertension, age 50+, or optometrist recommendation based on presenting symptoms.
  • Procedure: cataract surgery — Individuals diagnosed with high grade cataracts associated with moderate to sever visual impairment were offered cataract surgery, either through local surgery services or regional specialized vision services.

Primary Outcomes

  • Number of individuals screened (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-05
Completion: 2026-06
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: true
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Data Yakka, Inc.
Collaborators: Bangladesh Disaster Preparedness Centre
Principal Investigators:
  • Randall Scott Stafford, MD, PhD, MHS (PRINCIPAL_INVESTIGATOR) - Data Yakka, Inc.
Contact Information
Study Contact:
Mohammad Saidur Rahman, PhD
+880 1711-524722
Saidur1943@gmail.com
Hafizur Rahman
+880 1720-123458
hafiz@datayakka.io
Hasan Kabir
+880-1720-123458
Hasanhosifa1@gmail.com
Shashibhushan Clinic
Interventions
  • Diagnostic Test: Multimodal Screening for Eye Disease — The eye disease screening process involved twelve distinct steps were that organized through a corresponding software platform (electronic health record). These steps included: (1) community awareness campaign, (2) participant registration, (3) blood pressure and finger-stick blood glucose measurement, (4) basic vision test, (5) on-site optometrist evaluation, (6) obtaining informed consent for imaging, (7) fundus imaging, (8) automated AI-based disease detection, (9) on-site ophthalmologist examination, (10) remote eye specialist review, (11) on-site counselor discussion, (12) referral for local surgery. This standardized protocol promoted the alignment of eye screening with data gathering and ongoing follow-up eye care interventions. All participants were offered steps 1 to 5. Those participants eligible for fundus imaging (Steps 6-8) included those with diabetes, hypertension, age 50+, or optometrist recommendation based on presenting symptoms.
  • Procedure: cataract surgery — Individuals diagnosed with high grade cataracts associated with moderate to sever visual impairment were offered cataract surgery, either through local surgery services or regional specialized vision services.
Study Locations (1 sites)
Shashibhushan Clinic, Char Fasson, Bhola Bangladesh
Eligibility Criteria
Inclusion Criteria: * Age 35+ years * Residing in the Sub-District of Char Fasson in the Bhola District Exclusion Criteria: * Known eye disease diagnosis
Conditions Pulmonary Hypertension Due to Left Heart...
Phase PHASE4
Enrollment 38
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Milrinone inhalation — After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
  • Drug: Milrinone infusion — After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered

Primary Outcomes

  • mean arterial pressure (change in mean arterial pressure is recorded 10 minutes after milrinone administration after induction (T1), at the end of nebulization (T2), before cardiopulmonary bypass (T3) and after cardiopulmonary bypass(T4))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-05-20
Completion: 2025-05-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 38 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zagazig University
Principal Investigators:
  • Heba M EL-Asser, MD (PRINCIPAL_INVESTIGATOR) - Zagazig University
Contact Information
Study Contact:
Heba M EL-Asser, MD
01062393152
aseelaswad1@yahoo.com
Amany S abdelazeem, MD
01287220016
dola.salah2009@gmail.com
Heba M Elasser, MD
01062393152
aseelaswad1@yahoo.com
Zagazig University
Interventions
  • Drug: Milrinone inhalation — After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
  • Drug: Milrinone infusion — After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
Study Locations (1 sites)
Zagazig University, Zagazig, Sharqia Province 44519 Egypt
Eligibility Criteria
Inclusion Criteria: * Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\>55 estimated by using preoperative Doppler echocardiography Exclusion Criteria: Patients were excluded if they had surgery without CPB, preoperative hemodynamic instability (defined as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease , coagulopathy, and thromboembolic disease treated with anticoagulants
Conditions Hepatic Encephalopathy, Covert Hepatic E...
Phase NA
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Melatonin tablet 3 mg once daily — Participants will be instructed to take 3 mg regular acting (not orally dissolving) melatonin 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
  • Dietary Supplement: Thiamine — Participants will be instructed to take 100 mg regular acting (not orally dissolving) thiamine 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.

Primary Outcomes

  • Mean change in rapid eye movement (REM) sleep as a percentage of total sleep measured by polysomnography after melatonin vs thiamine (Approximately 4 weeks and 9 weeks, at polysomnography which marks the end of each treatment (melatonin or thiamine) assignment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-05
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: American Association for the Study of Liver Diseases
Principal Investigators:
  • Adam Buckholz, MD MS (PRINCIPAL_INVESTIGATOR) - NewYork-Presbyterian/Weill Cornell Medical College
Contact Information
Study Contact:
Adam Buckholz, MD MS
646-962-5483
apb9012@med.cornell.edu
Adam P Buckholz, MD MS
646-962-5483
apb9012@med.cornell.edu
NewYork-Presbyterian/Weill Cornell Medical Center
Cecilia Mero
cmm2002@med.cornell.edu
NewYork-Presbyterian/Weill Cornell Medical Center
Interventions
  • Dietary Supplement: Melatonin tablet 3 mg once daily — Participants will be instructed to take 3 mg regular acting (not orally dissolving) melatonin 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
  • Dietary Supplement: Thiamine — Participants will be instructed to take 100 mg regular acting (not orally dissolving) thiamine 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
Study Locations (1 sites)
NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York 10021 United States
Eligibility Criteria
Inclusion Criteria: * Cirrhosis with clinically significant portal hypertension or decompensation defined by Baveno VII criteria \[de Franchis R et al 2022\] * Adults over age 18 * CHE (defined by PHES≤ -4) or previously diagnosed HE * Disturbed sleep, with Pittsburgh Sleep Quality Index (PSQI) ≥5 * Possession of a "smart phone" with Bluetooth capability and ability to download the Oura application (Apple iOS version 14.0 or greater or Android version 8.0 or higher) Exclusion Criteria: * Use of melatonin regularly (3x per week) if unable/unwilling to discontinue for the study * Inability provide informed consent * Heavy current alcohol use (\>7 drinks weekly for women and 14 drinks weekly for men)' \-- Body mass index \>40 * Known prior sleep disorder including obstructive sleep apnea * Use of other prescription neuromodulating sleep aides * Self-reported pregnancy during study screening, as sleep physiology is different in this population
Conditions Chronic Obstructive Pulmonary Disease, P...
Phase PHASE2
Enrollment 126
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated by chance to either active tadalafil or an inactive identical capsule (placebo). Neither the Veteran nor the investigator will know whether the Veteran is taking tadalafil or placebo. Veterans will be followed closely in clinic or by telephone at 1, 2, 3, 4, 5, and 6 months, with attention to side effects and safety. At 1,3, and 6 months the investigators will repeat the questionnaires and testing of blood pressures in the lung and lung function. The investigators anticipate that the results of this study will determine whether tadalafil improves shortness of breath when added to usual medications for COPD.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Tadalafil — one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
  • Drug: Placebo — one or two encapsulated tablets of placebo po QD

Primary Outcomes

  • severity of patient-reported dyspnea (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-01
Completion: 2029-03-01
Eligibility
Age: 35 Years – 89 Years
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Collaborators: VA Boston Healthcare System, Atlanta VA Medical Center, VA Eastern Colorado Health Care System, VA Nebraska Western Iowa Health Care System
Principal Investigators:
  • Sharon I Rounds, MD (PRINCIPAL_INVESTIGATOR) - Providence VA Medical Center, Providence, RI
Contact Information
Study Contact:
Sharon I Rounds, MD
(401) 273-7100
sharon.rounds@va.gov
Ronald H Goldstein, MD
(857) 203-6578
Ronald.Goldstein@va.gov
Edward Dempsey, MD
303-399-8020
edward.dempsey@va.gov
Rocky Mountain Regional VA Medical Center, Aurora, CO
Interventions
  • Drug: Tadalafil — one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
  • Drug: Placebo — one or two encapsulated tablets of placebo po QD
Study Locations (5 sites)
Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado 80045 United States
Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia 30033-4004 United States
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts 02130-4817 United States
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska 68105-1850 United States
Providence VA Medical Center, Providence, RI, Providence, Rhode Island 02908-4734 United States
Eligibility Criteria
Inclusion Criteria: 1. Outpatients with COPD, defined as airflow limitation with post-bronchodilator obstruction on baseline visit spirometry, identified by FEV1/FVC \< 70% or \< the lower limit of normal (5th percentile of a normal population based on Global Lung Function Initiative reference equations), OR any emphysema on chest CT noted in a clinical radiology report confirmed by study investigator review. 2. Eligible subjects must have PH documented as follows: 1. Main Pulmonary Artery/Ascending Aorta (PA/A) diameter \> 0.90 on clinically available CT scans within 12 months OR 2. Main Pulmonary Artery diameter \> 30.8mm on clinically available CT scans within 12 months OR 3. outpatient echocardiography done within 6 months of enrollment demonstrating PA sys \> 34 mmHg OR 4. Mean Pulmonary Artery Pressure \> 20 on Right Heart Catheterization done within 6 months of enrollment and when Veteran is clinically stable. 3. Eligible subjects must be dyspneic, as quantitated by a score of at least 20 on the baseline UCSD Shortness of Breath Questionnaire, assessed at the time of the baseline visit. 4. Treatment with at least one long-acting bronchodilator for at least 4 weeks, assessed at the time of the baseline visit by chart review and patient interview. 5. Age 35-89 Years 6. Women of childbearing potential must meet one of the following criteria for the previous three months AND must have a negative pregnancy test on the day of testing. If more than 36 hours since the participant's last pregnancy test, they will be tested again at the study visit. 1. have been using a contraceptive measure (an intrauterine device (IUD), a contraceptive implant, oral contraceptives, barrier methods, or abstinence) 2. have a male partner with a vasectomy 3. have a tubal ligation procedure or a medical diagnosis (such as infertility) or therapies/procedures that precludes pregnancy (such as cancer treatments or endometrial ablation) 4. are in a same-sex relationship 5. have a male partner not capable of fathering children because of congenital anomalies, other surgery, or medical treatment 7. Women who are not considered to be of childbearing potential who have been surgically sterilized (for example: removal of ovaries or fallopian tubes, or hysterectomy) or are post-menopausal (no menstrual period for more than 6 months). Exclusion Criteria: 1. Diagnosis of PH in the following subgroups of the updated WHO Clinical Classification: 1. Group 1 (Idiopathic, heritable, drug- or toxin-induced, Pulmonary Arterial Hypertension associated with connective tissue disease, congenital heart disease) 2. Group 2 (left atrial hypertension) 3. Group 3 PH not attributable to COPD 4. Group 4 (chronic thromboembolic PH) or other forms of PH not associated with primary lung disease. 2. Systemic hypotension in the ambulatory setting (at least 3 reproducible measurements of systolic BP \<89 mmHg, recorded by a health care provider over 1 week). 3. Moderate or severe hepatic impairment (Child-Pugh B and C). 4. Severe renal insufficiency (GFR \<30 ml/min/1.73 m2) 5. Echocardiography within 6 months showing greater than moderate aortic stenosis (aortic valve area \<1.0 cm2), greater than moderate mitral regurgitation, or diastolic dysfunction (Any two of the following: Average E/e' \>14, Septal e' velocity \< 7 or lateral e' velocity \<10, LA volume index \> 34 ml/m2). LVEF \< 50%. Any aortic or mitral valve replacement. 6. Any acute or chronic impairment (other than dyspnea) that limits ability to comply with the study requirements. 7. Current unstable angina, myocardial infarction or stroke within 6 months. 8. Requirement for nitrate therapy for any clinical indication. 9. Active prescription for a PDE-5 inhibitor or other pulmonary vasodilator other than oxygen as a PH treatment. 10. History of the following retinal disorders: retinitis pigmentosa, non-arteritic anterior ischemic optic neuropathy, or crowded optic disc noted on ophthalmology examinations recorded in CPRS. 11. Contraindications: PDE-5i allergy, penile anatomical deformations, sickle cell anemia, multiple myeloma, leukemia, bleeding disorders, active peptic ulcer disease, retinitis pigmentosa or other retinal disorders listed above. In accordance with 38 USC 7332, this information will be kept confidential and will not be disclosed in presentations, publications, or any other dissemination of the study results, or to anyone outside of the IRB-approved study team. 12. Use of any of the following: rifampin, systemic anti-fungal azole agents, protease inhibitors, phenobarbital, dilantin. 13. Pregnant, possibly pregnant by report, or if breastfeeding. If found to be pregnant at the study visit, the study visit will not be conducted. 14. Pulmonary veno-occlusive disease 15. Hypoxia (reproducible ambulatory SaO2 \< 90% on supplemental oxygen at rest recorded by a health care provider over 1 week). 16. Diagnosis of Obstructive Sleep Apnea without a prescription for treatment. 17. Newly prescribed (less than 4 weeks duration) bronchodilator or diuretic therapy or new enrollment in pulmonary rehabilitation at the time of Baseline. 18. Students, VA employees, persons with impaired decision making, illiterate and non-English speakers, and terminally ill patients. 19. COPD or CHF exacerbation within the past 4 weeks. 20. On-going therapy with doxazosin. Women of childbearing potential must have a documented negative pregnancy test and must be using adequate contraception during the study and for 9 months afterward. Monthly pregnancy tests will be done, and compliance with contraception use will be documented at the telephone and clinic visits. Should a female become pregnant at any time during the study, the study medication will be discontinued. Doxazosin use will be defined as current active prescription and usage of Doxazosin or planned trial (pending prescription) of Doxazosin for treatment of benign prostatic hypertrophy, systemic hypertension, or other indication. A list of alpha-1 antagonists (ex. prazosin, doxazosin, tamulosin, terazosin, etc.) will be included in the patient study medication handout to prompt the patient to avoid any new usage of these drugs during the trial period. On-going therapy with doxazosin is an exclusion criterion due to greater risk of hypotension.
Conditions Normal Tension Glaucoma
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess whether deep sclerectomy is as effective in lowering intraocular pressure (IOP) as trabeculectomy in patients with normal tension glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Trabeculectomy — trabeculectomy glaucoma surgery
  • Procedure: Deep Sclerectomy — deep sclerectomy glaucoma surgery

Primary Outcomes

  • Success Rate (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-05-31
Completion: 2029-05
Eligibility
Age: 55 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Helsinki University Central Hospital
Contact Information
Study Contact:
Nina Lindbohm, MD, PhD
+358 9 4711
nina.lindbohm@hus.fi
Helsinki University Central Hospital
Interventions
  • Procedure: Trabeculectomy — trabeculectomy glaucoma surgery
  • Procedure: Deep Sclerectomy — deep sclerectomy glaucoma surgery
Study Locations (1 sites)
Helsinki University Central Hospital, Helsinki, 00990 Finland
Eligibility Criteria
Inclusion Criteria: * Signed Informed Consent * Normal Tension Glaucoma with typical nerve fiber layer defects in red-free photographs and/or optical coherence tomography (OCT) and possible equivalent visual field defects, IOP never more than 21 mmHg, and open anterior chamber angle * Glaucoma unstable with current medication assessed by a glaucoma specialist Exclusion Criteria: * Secondary Glaucoma e.g. due to previous injury or uveitis * Exfoliation syndrome * Pigment dispersion syndrome * Previous transscleral or endoscopic cyclophotocoagulation * Previous other glaucoma surgery * Previous retinal detachment * Previous intraocular surgery like vitrectomy and other retinal surgery * Wet age-related macular degeneration * Diabetic retonopathy * Previous corneal transplant or previous refractive surgery * Fuchs' dystrophy and other abnormalities compromising corneal clarity like scars * The patient does not want to participate in the study * The patient does not speak Finnish, Swedish or English * Dementia * Only eye with vision worse than 20/200 or loss of central visual field
Conditions Hypertension
Phase PHASE2
Enrollment 93
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: ALN-AGT01 RVR — ALN-AGT01 RVR will be administered subcutaneously (SC)
  • Drug: Placebo — Placebo will be administered SC
  • Drug: Zilebesiran — Zilebesiran will be administered SC

Primary Outcomes

  • Part A: Percentage recovery from baseline in serum AGT (Up to Day 4)
  • Part B: Percentage recovery from baseline in mean seated office SBP (At Day 4 and Day 7)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-04-27
Completion: 2028-10-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 93 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alnylam Pharmaceuticals
Collaborators: Hoffmann-La Roche
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Alnylam Pharmaceuticals
Contact Information
Study Contact:
Alnylam Clinical Trial Information Line
1-877-ALNYLAM
clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line
1-877-256-9526
clinicaltrials@alnylam.com
Interventions
  • Drug: ALN-AGT01 RVR — ALN-AGT01 RVR will be administered subcutaneously (SC)
  • Drug: Placebo — Placebo will be administered SC
  • Drug: Zilebesiran — Zilebesiran will be administered SC
Study Locations (3 sites)
Clinical Trial Site, Lake Forest, California 92630 United States
Clinical Trial Site, Tampa, Florida 33613 United States
Clinical Trial Site, Savannah, Georgia 31405 United States
Eligibility Criteria
Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria * Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg * Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks Both Parts: Exclusion Criteria * Has known secondary hypertension or serum potassium more than 5 mmol/L * Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2 Note: other protocol defined inclusion / exclusion criteria apply
Conditions Chronic Kidney Disease, Hypertension
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Intensive Patient Referral and Education Program prior to Renal Replacement Therapy (iPREP-RRT) is a 12-week intervention that identifies hospitalized African Americans with advanced chronic kidney disease (CKD) and provides them with hospital- and community-based education, navigation and self-management support. Participants will be randomized to the iPREP-RRT intervention versus enhanced usual care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Double

Interventions / Regimen

  • Behavioral: In-Person Patient Education — In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
  • Behavioral: Commitment to Change — Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
  • Behavioral: Blood pressure monitoring — Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
  • Behavioral: Written Patient Education — Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
  • Behavioral: Text-based reinforcement for CKD self-management — Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
  • Behavioral: Community-based education session, reinforcement for self-management — Patient educator will use provide a "booster" session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
  • Behavioral: Text-based reinforcement for general health self-management — Patient educator will use text messages to send general health management messages

Primary Outcomes

  • Kidney Disease Knowledge Questionnaire (KIKS) (Baseline, 1 day Post Brief Intervention, Week 4, Week 12, Week 16)
  • ESRD Knowledge (Baseline, 1 day Post Brief Intervention, Week 4, Week 12, Week 16)
  • Blood Pressure Knowledge (Baseline, 1 day Post Brief Intervention, Week 4, Week 12, Week 16)
  • CKD Self-Management (Baseline, Week 8, Week 12, Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-04
Completion: 2026-06-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact Information
Study Contact:
Milda Saunders, MD
773-702-5941
msaunders@uchicago.edu
University of Chicago Medical Center
Akilah King, MSW
Akilah.King@bsd.uchicago.edu
University of Chicago Medical Center
Milda R. Saunders, MD
University of Chicago Medical Center
Interventions
  • Behavioral: In-Person Patient Education — In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
  • Behavioral: Commitment to Change — Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
  • Behavioral: Blood pressure monitoring — Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
  • Behavioral: Written Patient Education — Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
  • Behavioral: Text-based reinforcement for CKD self-management — Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
Study Locations (1 sites)
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Eligibility Criteria
Inclusion Criteria: * Patients over the age of 18 and under 70 * Admitted to the University of Chicago inpatient general medicine service * Likely hospital stay greater than 48 hours * Diagnosis of advanced CKD (Stage 3B or above, as determine by problem list, ICD- 10 codes or eGFR\<45 during admission and from previous medical encounters) * Self-identify as Black or African American Exclusion Criteria: * Non-English speaking * Unable to communicate due to current medical status * Unable to consent due to mental status * Expected hospital stay less than 24 hour * Current admission in ICU

CVD/PH and Voice Characteristics

NCT07311044
Recruiting
Conditions Pulmonary Hypertension, Cardiovascular D...
Phase Not Applicable
Enrollment 7000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine the association between patient voice signal characteristics and the presence and severity of pulmonary hypertension in patients referred for elective clinically indicated echocardiography for at Mayo Clinic MN.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Number of confirmed pulmonary hypertension diagnoses based on voice recording analysis (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-01-08
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 7000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Amir Lerman, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Diana Albers
507-255-6884
albers.diana2@mayo.edu
Amir Lerman, M.D.
lerman.amir@mayo.edu
Diana Albers
507-255-6884
albers.diana2@mayo.edu
Mayo Clinic
Interventions
N/A
Study Locations (1 sites)
Mayo Clinic, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * All individuals who present for a routine elective, clinically indicated, diagnostic echocardiogram at the echocardiography laboratory at Mayo Clinic * All individuals who have had a clinically indicated, diagnostic echocardiogram at the echocardiography lab at Mayo Clinic before a scheduled procedure in the cardiac catheterization lab at Mayo Clinic * All individuals who have had a clinically indicated diagnostic echocardiogram at the echocardiography lab at Mayo Clinic and have an appointment in any CV outpatient clinic. Exclusion Criteria: * Known history of voice disorder either primary or secondary to neuromuscular or other pathology * Patients under the age of 18 years
Conditions Liver Cirrhosis, Portal Hypertension
Phase NA
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

1. Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Objective The purpose of the study is to examine the effects of Handgrip strength on portal vein and left gastric vein pressure, blood flow velocity and direction in patients with liver cirrhosis, as well as its hemodynamic impact on gastroesophageal varices. 3. Method Study Design: Interventional study. Detection Timing: Hemodynamic indices were measured simultaneously after patients achieved their maximum handgrip strength. Participants were divided into three groups based on the assessment methods. Group 1 (Portal Pressure Measurement Group): Before the placement of TIPS, the pressures of the portal vein and left gastric vein were measured, both before and after the handgrip strength test. Group 2 (Doppler Ultrasound Measurement Group): Measurements of portal flow velocity and direction were taken before and after the handgrip strength test, based on Doppler ultrasound. Group 3 (Endoscopic Ultrasound Measurement Group): Measurements of blood flow volume and direction in esophagogastric varices were conducted before and after the handgrip strength test, based on endoscopic ultrasonography. The inclusion and exclusion criteria were described. 4. Elaboration of the Research Hypothesis 4.1. Core Hypothesis The handgrip strength level in patients with liver cirrhosis is correlated with portal venous system hemodynamic indices. Specifically, enhanced handgrip strength may affect portal hypertension and the hemodynamics of varicose veins by improving systemic muscle function or circulatory status. 4.2. Speculation on potential mechanisms Association between muscle function and circulation: As a representative of systemic muscle function, increased handgrip strength may reflect an increase in cardiac output or changes in splanchnic vascular resistance, thereby influencing portal venous hemodynamics. Effects on varicose veins: Improved handgrip strength may reduce blood flow velocity or diameter of esophagogastric varices by decreasing splanchnic congestion or regulating local vascular tension, thus lowering the risk of variceal rupture and bleeding. Role of compensatory mechanisms: Muscle wasting is common in decompensated cirrhosis. Patients with higher handgrip strength may have better compensatory capacity, and the degree of hemodynamic disorder in their portal venous system may be less severe. Conclusion This study uses a multi-method grouping design to first explore the association between handgrip strength and portal venous hemodynamics in cirrhotic patients. The hypothesis is based on the potential regulatory role of muscle function in the circulatory system, which is expected to provide a new non-invasive indicator for clinical assessment of portal hypertension risk.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Device: Jamar Hand Dynamometer, Hand Dynamometer — Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests

Primary Outcomes

  • portal pressure (through study completion, an average of 3 minutes)
  • left gastric vein pressure (through study completion, an average of 3 minutes)
  • portal flow velocity (Before the handgrip strength test, and during the maximum handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the HGS)
  • Portal vein blood flow direction (Before the handgrip strength test, and during the maximum handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the HGS)
  • Blood flow velocity in esophageal varices (through study completion, an average of 3 minutes)
  • Blood flow direction of esophageal varices (through study completion, an average of 3 minutes)
  • Diameter of esophageal varices (through study completion, an average of 3 minutes)
  • Heart rate (through study completion, an average of 3 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-17
Completion: 2027-08-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanxi Provincial People's Hospital
Collaborators: The First Affiliated Hospital of Shanxi Medical University, The Third People's Hospital of Taiyuan, The First Affiliated Hospital of Henan University of Science and Technology
Contact Information
Study Contact:
Mingyuan Zhao, M.D.
+86 134 8537 1098
zmy255255@163.com
Yaojian Rao, M.D.
86+13698817187
yaojian8162021@163.com
The First Affiliated Hospital of Henan University of Science and Technology
Mingyuan Zhao
86-13485371098
zmy255255@163.com
Shanxi Provincial People's Hospital
Interventions
  • Device: Jamar Hand Dynamometer, Hand Dynamometer — Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests
Study Locations (2 sites)
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003 China
Shanxi Provincial People's Hospital, Taiyuan, Shanxi 030012 China
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years old * Clinically diagnosed with liver cirrhosis * Endoscopic observation to determine the presence of esophagogastric varices * Only eligible for the portal vein pressure measurement group if there are no signs of variceal bleeding for at least 14 days * Participant or guardian is capable of comprehending the study protocol, willing to participate, and able to provide written informed consent Exclusion Criteria: * Severe congestive heart failure, or severe untreated valvular heart disease * Moderate to severe pulmonary hypertension * Uncontrolled systemic infection * Lesions (e.g., cysts) or tumors in the liver parenchyma that preclude TIPS creation * Overt hepatic encephalopathy * Unrelieved biliary obstruction * Child-Pugh score \> 13 * MELD score \> 18 * INR \> 5 * Platelet count \< 20 ×109/mm3 * No gastrointestinal bleeding (suitable for the ultrasound examination group and the endoscopic ultrasonography group) * Participants who had undergone hand or wrist surgery within the previous 3 months or were unable to hold the dynamometer with the testing hand were excluded from the study.